U.S. Markets closed

CorMedix, Inc. (CRMD)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.45+0.02 (+4.31%)
At close: 4:02PM EDT
People also watch

CorMedix, Inc.

1430 US Highway 206
Suite 200
Bridgewater, NJ 07921
United States

Full Time Employees14

Key Executives

Mr. Khoso BaluchChief Exec. Officer and Director208.32kN/A59
Mr. Robert W. CookChief Financial OfficerN/AN/A61
Mr. John L. Armstrong Jr., MBAHead of HR and Exec. VP of Technical OperationsN/AN/A73
Dr. Judith R. Abrams M.D., FRCPCChief Medical OfficerN/AN/A57
Mr. John OrtizVP of Regulatory Affairs and Quality AssuranceN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Bridgewater, New Jersey.

Corporate Governance

CorMedix, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 6. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.